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Abstract
Background: Tuberculosis is one of the leading causes of morbidity and mortality in developing countries. Analysis
of the host immune response may help with generating point-of-care tests for personalised monitoring. Thus, the
aim of this study was to assess the relationship between immune activation markers: C-reactive protein (CRP), Beta2
microglobulin (B2M) and Neopterin, disease severity prior to treatment and response to therapy in adult pulmonary
TB patients.
Methods: HIV negative adult pulmonary TB index cases (n = 91) were recruited from the TB clinic at MRC, The
Gambia. Plasma samples were collected at enrolment and at 2 and 6 months following TB treatment initiation. An
enzyme linked immunosorbent assay (ELISA) was performed for evaluation of CRP, B2M and Neopterin levels and
correlated with clinical and microbiological parameters including strain of infection. Disease severity was determined
using Chest X-ray (CXR), Body Mass Index (BMI) and sputum smear grade.
Results: Plasma levels of all three markers were highly elevated in patients at recruitment and declined significantly
during TB therapy. No correlation with disease severity was seen at recruitment. CRP showed the most significant
decrease by 2 months of treatment (p < 0.0001) whereas levels of B2M and Neopterin showed little change by
2 months but a significant decrease by 6 months of treatment (p = 0.0002 and p < 0.0001 respectively). At recruitment,
B2M levels were significantly higher in subjects infected with Mycobacterium africanum (Maf) compared with those
infected with Mycobacterium tuberculosis sensu stricto (Mtb) (p = 0.0075). In addition, while CRP and Neopterin showed
a highly significant decline post-treatment regardless of strain (p < 0.0001 for all), B2M showed differential decline
depending on strain (p = 0.0153 for Mtb and p = 0.0048 for Maf) and levels were still significantly higher at 6 months in
Maf compared to Mtb infected subjects (p = 0.0051).
Conclusion: Our findings suggest that activation markers, particularly CRP, may have a role in identifying good
response to TB therapy regardless of the strain of infection and could be further developed as point-of-care tests. In
addition, B2M levels may allow differentiation between Mtb and Maf-infected subjects.
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Background
Tuberculosis (TB) is one of the leading global causes of
morbidity and mortality, particularly in Sub-Saharan
Africa with 1.5 million deaths per year [1]. Despite many
advances in treatment and campaigns such as Directly
Observed Treatment Short course (DOTS) by the World
Health Organisation (WHO), difficulty in diagnosis,
non-adherence to treatment, emergence of multi-drug
resistance (MDR) strains and TB/HIV co-infection have
all fuelled the spread of the disease [2]. The causative
pathogen, Mycobacterium tuberculosis complex (MTBC)
includes M. tuberculosis (Mtb), M. africanum (Maf), M.
canettii, M. bovis, M. microti, M. caprae, M. orygis, and
M. pinnipedii [3] with Mtb and Maf the most common
strains in human diseases. In West Africa about half of
pulmonary TB cases are caused by Maf [4–6]. Though
the disease produced by both strains looks similar [4],
they have significant differences in their genomes par-
ticularly in the Region of Difference 1 (RD1) containing
crucial T cell epitopes. In this regard, Maf infected sub-
jects were observed to be less responsive to both ESAT-
6 and TST compared to Mtb infected counterparts [5]
and are more likely to have severe cavitation on chest x-ray
[5]. Two recent studies from Gambia have shown compar-
able immune profiles regardless of infecting strain at base-
line but significant divergence post-treatment at the
cellular [7], metabolomic [8] and transcriptomic [8] levels.
Due to the intensive nature of anti-TB therapy and these
differences in therapy response depending on the strain of
infection [7, 8], a point-of-care test that allows personalised
monitoring of treatment response would be beneficial.
Previous studies analysing response to therapy have
focussed on either C-reactive protein (CRP) or cytokine/
chemokine profiles. A recent meta-analysis of cytokine
markers has shown marked variation between studies
due to low subject numbers and differences in follow-up
times [9]. Activation markers such as CRP, Neopterin
and Beta2 microglobulin (B2M) may hold the key for a
fast, effective method of treatment monitoring at the
point-of-care setting. CRP is an acute phase reactant and
is a robust indicator of immune system activity. Its
serum concentration has been used as a marker of
inflammation in patients with diabetes mellitus [10],
tuberculosis [11] and asthma [12]. Breen et al found that
an elevated CRP detected 85 % of proven tuberculosis
cases in the UK [13] raising the possibility of using CRP
as a point-of care test. Neopterin is released by monocytes/
macrophages when activated by Interferon-γ (IFN-γ) and
acts as a mediator of cell immunity against intracellular
pathogens [14]. Previous studies have shown increased
serum Neopterin level in HIV/TB co-infected patients be-
fore anti-TB treatment and a decline after treatment [15].
In another study, serum Neopterin and IL-2 were observed
to decline with TB treatment [16, 17]. B2M is a component
of major histocompatibility (MHC) class 1 molecules
found on the surface of all nucleated cells. It is also found
in a free state in various body fluids suggesting an influence
in disease pathology with a rise observed in the presence of
glomerular impairment, or lymphocyte activation [16]. Past
studies have shown a correlation with HIV disease progres-
sion [18, 19] but few studies have evaluated its role in TB.
One study did, however, show clinical utility for treatment
monitoring in HIV negative TB patients, particularly those
with high levels of B2M at presentation [20].
Identification of markers that correlate well with re-
sponse to TB therapy, will aid in the development of
tests to improve personalised medicine. Thus the aim of
this study was to determine the levels of CRP, Neopterin
and B2M in relation to pulmonary tuberculosis disease
severity at recruitment and changes in response to TB
treatment in a cohort of TB patients from The Gambia.
Due to the prevalence of Mycobacterium africanum
(Maf) in this region [8], we were also able to determine
differential responses based on the strain of infection
before and after treatment initiation.
Methods
Study participants
Ninety-one adult pulmonary TB index cases with newly
diagnosed smear-positive pulmonary TB were recruited
from the TB clinic at the Medical Research Council
(MRC) Unit, The Gambia. Participants provided written
informed consent prior to collection of samples. Clinical
evaluation, symptom screening, Body Mass Index (BMI),
and chest posterior-anterior x-ray were performed and
heparinised blood and sputum were collected for immuno-
logical and microbiological evaluations respectively. A
Chest X-ray showing 1–2 infected lobes was considered
minimal; 3 to 4 infected lobes with 1 cavitation considered
moderate; and 5–6 lobes infected with cavitation consid-
ered advanced disease (for analysis purposes a nominal
scale of 1–6 was used to define the number of lobes infil-
trated). All subjects were treated according to the Gambian
National Tuberculosis and Leprosy Control Programme’s
conventional therapy of 2 months intensive treatment with
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, followed
by a second phase of four months with only Isoniazid and
Rifampicin (2HRZE/4HR). Following initiation of standard
TB treatment, participants were followed up at 2 and
6 months for further blood draw and sputum smear mi-
croscopy and culture to determine treatment response.
Chest x-ray was performed at 2 months but not at
6 months follow-up. All specimens sent for mycobacterial
confirmation were stained for acid-fast bacilli (AFB) by
Ziehl-Neelsen (ZN) stain and cultured in liquid culture
media (BACTEC MGIT, Becton Dickinson, USA). Spoligo-
typing was also performed to determine the strain of infec-
tion as previously described [8]. By the end of treatment all
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study subjects were confirmed microbiologically cured
(negative) by sputum culture. The study was approved by
the Gambian government/MRC joint ethics committee.
Sample preparation
Plasma was collected and stored at -20 °C prior to analysis.
On the day of sample analysis, the frozen plasma was
thawed and centrifuged at 1500 rpm to remove debris.
Evaluation of activation markers in plasma
Samples were evaluated using commercially available
kits for plasma CRP, B2M (both from Immunology Con-
sultants Laboratory, USA), and Neopterin (IBL Inter-
national, Germany). ELISAs were performed according
to the manufacturer’s instructions. All samples were run
in duplicates and analysed using Softmax Pro 4.7.1
(Molecular Devices, USA). A four-parameter logistic
curve was used to interpolate test samples values from
the standard curve at 450 nm wave length.
Measurement of C-reactive protein and Beta2 microglobulin
The microtiter plates provided were pre-coated with
monoclonal antibodies specific to CRP or B2M. Samples
were added to each well in duplicate and incubated for
15 min. A washing step was performed to remove the
unbound proteins then secondary antibodies conjugated
with horseradish peroxidise (HRP) were added for a fur-
ther 15 mins. Following another wash, chromogenic sub-
strate 3, 3’, 5’, 5’-tetramethylbenzidine (TBM) was added
and incubated for 10 min, resulting in a colour change.
A colour development stop solution (0.3 M sulfuric acid)
was then added and the plate read at 450 nm.
Measurement of neopterin
The Neopterin concentrations were determined using a
competitive ELISA. Microtiter strips were pre-coated
with goat-anti-rabbit Neopterin antibody. 20 μl each of
sample, standard or controls were added to appropriate
wells and incubated for 90 mins. 100 μl of enzyme con-
jugate and 50 μl of neopterin antiserum were then added
to each well. Following a wash to remove unbound anti-
bodies, 150 μl of TMB substrate solution was added and
incubated at room temperature (RT) for 10 mins. After
the incubation, the reaction was stopped by the addition
150 μl of TBM Stop Solution and briefly mixed by gently
shaking the plate. The concentration of Neopterin was
measured within 15 min at 450 nm optical density. The
results were acceptable only when the controls were
within defined ranges.
Statistical analysis
The results were analysed with GraphPad Prism 6 (Soft-
ware MacKiev, USA) using Wilcoxon Ranked sum test
for paired values (ie pre and post-treatment for the same
subject) or Mann-Whitney U-test for between subject
comparisons (ie Maf versus Mtb-infected). Multivariable
analysis was performed to adjust for age, sex and BMI
using SPSS (v22, IBM, USA). A p-value of ≤0.05 was
considered significant. Correlation with clinical and




Samples from 91 HIV negative subjects analysed (Table 1).
The median (interquartile range (IQR)) age was 29 years
(22–38) and 64 % were male. Body Mass Index (BMI) at
recruitment was (median (IQR)) 18.6 kg/m2 (17.3–19.3)
and this significantly increased by 6 months of treatment
(19.6 kg/m2 (1.6–22.1; p = 0.0374; Table 1). The majority
of subjects at recruitment had a smear grade of 3 (50 %),
with all samples negative by 2 months for those analysed
(not all patients could produce sputum for analysis at 2
and 6 months). CXR scores were highly variable with the
majority of subjects having moderate to extensive disease
at recruitment (79 %), which resolved to 45 % having min-
imal and 55 % moderate disease by 2 months, and 83 and
17 % with minimal versus moderate disease by 6 months
(for those with readings available; Table 1).
CRP, Neopterin and B2M levels pre and post-treatment
At recruitment, CRP had significantly higher levels than
the other two markers (median (IQR) = 108(64–158) μg/
ml compared to 13(8–24) ng/ml for Neopterin and
2.9(1.9–4.1) μg/ml for B2M (Fig. 1a–c). We found no
Table 1 Patient characteristics at recruitment, 2 and 6 months
of treatment
Time-point Recruitment 2 months 6 months
N= 91 91 91
Age (median (IQR)) 29 (22–38) - -
Males n(%) 58(64) - -
BMI (median (IQR)) 18.6 (17.3–19.3) 19.1 (17.2–21.8) 19.6 (18.6–22.1)*
Smear grade n (%)
Undetectable 0(0) 57(62) 22(24)
1+ 24(26) 0(0) 0(0)
2+ 22(24) 0(0) 0(0)
3+ 46(50) 0(0) 0(0)
Unknown 0(0) 35(38) 69(76)
X-ray score n (%)
Minimal 19(21) 30(33) 24(26)
Moderate 50(55) 36(40) 5(5)
Extensive 22(24) 0(0) 0(0)
Unknown 0(0) 24(26) 63(69)
* = p < 0.05 compared to pre-treatment; BMI body mass index, IQR
interquartile range
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correlation with CXR, BMI or smear grade for any of
the activation markers at recruitment (data not shown).
Plasma levels of all three markers were significantly re-
duced during anti-tuberculosis therapy. CRP showed the
most notable decrease by 2 months of treatment; (p <
0.0001; Fig. 1a) and this was further reduced by 6 months
(p < 0.0001 compared to baseline and p = 0.0029 com-
pared to 2 months; Fig. 1a). In contrast, B2M showed a
gradual decline by 2 months (p = 0.0234) with a more
significant decline by 6 months (p = 0.0002 compared to
baseline and p = 0.0036 compared to 2 months; Fig. 1c).
Neopterin showed no significant difference by 2 months
but was significantly decreased by 6 months compared
to both baseline (p < 0.0001) and 2 months (p = 0.0218;
Fig. 1b). By 6 months, the mean (SD) fold change from
baseline was 35.6(55.0) for CRP, 3.9 (4.9) for Neopterin
and 1.4 (0.5) for B2M. These values were still highly
significant after adjusting for age, sex and BMI (data
not shown).
Differential expression of activation markers in subjects
with different strains of infection
We next analysed subjects based on their strain of infec-
tion. Both CRP and Neopterin showed no difference in
levels between Mtb and Maf infected subjects (Fig. 2a
and b) with both showing a highly significant decrease
between baseline and 6 months. However, analysis of
B2M levels showed significant differences in Mtb versus
Maf-infected subjects at both recruitment and 6 month
time-points. Levels in Maf-infected subjects were higher
at both time-points compared to Mtb (median[IQR] =
2.7[1.96–3.17] and 1.8[1.5–3.1] for Mtb at recruitment
and 6 months compared to 3.5[2.6–4.4] and 2.7[2.2–3.6]
for Maf at recruitment and 6 months (p = 0.0075 and
p = 0.0051 for Mtb versus Maf at 0 and 6 months respect-
ively; Fig. 2c). We also found a significant but differential
decline at 6 months depending on the strain of infection
(p = 0.0153 and p = 0.0048 for Mtb and Maf-infected sub-
jects respectively).
Discussion
Analysis of plasma activation markers before and after
initiation of anti-TB treatment has not been studied previ-
ously in The Gambia. We analysed HIV negative adults
with confirmed pulmonary TB at recruitment, at 2 months
(completion of the intensive phase of chemotherapy) and
at 6 months (completion of the continuation phase of
treatment). By 6 months, all subjects’ sputum samples
were culture negative for AFB, indicating treatment suc-
cess; and this correlated with significantly lower levels of
plasma CRP, Neopterin and B2M. CRP showed the shar-
pest decline by 2 months of treatment whereas Neopterin
and B2M had a gradual decline within the first 2 months,
then a sharper decline between 2 and 6 months. When
Fig. 1 Decrease in plasma activation marker levels in response to TB
therapy. Plasma from adult TB cases was assessed by ELISA for levels
of C-reactive protein (a), Neopterin (b) and Beta2-microglobulin (c)
before and after initiation of TB therapy. n = 91. Bar indicates median.
Data were analysed using Friedman repeated measures test with
post-test comparisons
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subjects were analysed based on their strain of infection
no difference was seen in CRP and Neopterin levels but
B2M levels were significantly higher in Maf-infected com-
pared to Mtb-infected subjects at both recruitment and
6 months of therapy. Our data indicate that CRP may be a
useful marker for pulmonary TB treatment monitoring
and future studies should analyse earlier time-points post-
treatment initiation. In addition, B2M is the first immune
activation marker shown to differentiate between Maf and
Mtb-infected subjects at recruitment and follow-up. These
differences may relate to the reduced ability of Maf to se-
crete ESAT-6 [5], which has been shown to affect B2M
production [21]
One of the major predictors of response to therapy in
TB is disease severity prior to treatment initiation [22].
In our cohort, there was no correlation between any of
the activation markers studied and extent of disease by
CXR or smear grade at recruitment. We also did not see
a relationship between levels of any of the markers at
treatment and subsequent decline post-treatment. It is
possible that measurement of the markers at shorter in-
tervals and earlier time points might detect differences
in the decline according to the initial values.
Our study supports previous findings showing high
levels of CRP in patients at enrolment and a decline with
treatment. One subject showed an increase in their CRP
levels but a decline in Neopterin and B2M following
treatment initiation. The reason for this is unclear but
the subject may have had another concurrent pro-
inflammatory condition that only elicited changes in
CRP. A study with a larger sample size that includes
drug resistant cases and measurements at shorter inter-
vals may help to fully evaluate the clinical utility of each
of the markers. Interestingly, there was no difference in
levels of CRP and Neopterin in subjects infected with
different strains of bacteria. West Africa has a preva-
lence of Maf infection [8], which has been shown to be
less virulent than Mtb resulting in different clinical pre-
sentations and response to therapy. Interestingly, no
studies to date have been able to find differences in any
immunological or transcriptomic marker at recruitment
between these two strains [7, 8]. Our finding that B2M
can differentiate between Maf and Mtb infected subjects
both at recruitment and after therapy opens new ave-
nues for monitoring of immunity based on different
strains. Further work should include subjects with other
strains of infection such as Beijing, which is highly viru-
lent [23].
Conclusions
In conclusion, we have shown the clinical utility of three
activation markers for monitoring of pulmonary TB
treatment responses in The Gambia. Our findings
suggest that activation markers, particularly CRP, may
have a role in identifying good response to TB ther-
apy regardless of the strain of infection and could be
further developed as point-of-care tests. In addition,
we have been able to describe for the first time a
marker, B2M which can differentiate between Mtb
and Maf-infected subjects.
Fig. 2 Differential levels of activation markers depending on the
strain of infection. Plasma from adult TB cases was assessed by ELISA
for levels of C-reactive protein (a), Neopterin (b) and Beta2-microglobulin
(c) before and after initiation of TB therapy. The strain of infection was
determined using spoligotyping. Maf =Mycobacterium africanum;
Mtb =Mycobacterium tuberculosis sensu stricto. n = 29 for both
groups. Bar indicates median. Data were analysed using Wilcoxon
ranked sums test within groups and Mann-Whitney U-test
between groups
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